Global Benign Prostatic Hyperplasia Prostate Treatment Market Size, Forecast, and Trend Highlights Over 2025-2037
Benign Prostatic Hyperplasia Prostate Treatment Market size is anticipated to expand from USD 7.86 billion to USD 16.09 billion, demonstrating a CAGR of around 5.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of benign prostatic hyperplasia prostate treatment is estimated at USD 8.22 billion.
In October 2024, NLM published an article stating that the histological incidence of BPH at autopsy in males is between 50% to 60% in their 60s, accelerating to 80% to 90% of those older than 70 years of age. BPH is a common disorder experienced by aging men and a frequent cause of lower urinary tract symptoms. According to Johns Hopkins Medicine, as many as 200,000 prostatectomy procedures are carried out yearly in the U.S. for BPH. Furthermore, in June 2024, the National Institute of Diabetes and Digestive and Kidney Diseases stated that BPH rarely causes symptoms in men younger than age 40, yet, it is the most common prostate problem in men older than age 50.
The global market is majorly driven by the rising geriatric population, prevalence of lifestyle-related conditions such as obesity and diabetes, and technological innovations including laser therapies, drug formulations, and prostatic implants. In May 2024, Teleflex Incorporated presented multiple clinical studies at the 2024 American Urological Association Annual Meeting. These studies add to the clinical evidence around the safety, efficacy and patient experience with a Prostatic Urethral Lift (PUL) using the UroLift System for benign BPH.
Benign Prostatic Hyperplasia Prostate Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Spiking cases of urinary tract infection: According to the NLM May 2021, UTIs are common, with an annual US incidence of 12% among women and 3% among men. It further states that the lifetime prevalence of UTI in men is about 12%. Prevalence of UTIs, mainly among the aging male population, is promoting early diagnosis and treatment of underlying BPH conditions. This is boosting the demand for both pharmacological treatments and minimally invasive procedures, accelerating market growth.
- Increasing healthcare expenditure per capita: Improvement in the healthcare infrastructure, followed by the increase in the healthcare expenditure around the world, is upgrading treatment with better technology available for the patients. Therefore, it is expected to surge the growth of the global benign prostatic hyperplasia (BPH) prostate treatment market.
Per Capita Medical Expenses, USD, 2022
|
Country |
Expense |
|
United States |
12,555 |
|
Germany |
8,011 |
|
France |
6,630 |
|
Australia |
6,372 |
|
Canada |
6,319 |
|
United Kingdom |
5,493 |
|
Japan |
5,251 |
Source:Peterson-KFF Health system Tracker
Challenges
- Stringent government regulations regarding the sales and consumption of medicines: Strict approval processes, pricing controls, and compliance requirements can delay product launches and limit the availability of advanced therapies. Additionally, regulatory barriers can increase the overall cost of treatment, affecting patient accessibility, especially in price-sensitive regions.
- Lack of awareness of the disease in developing countries: This hampers early diagnosis and timely treatment significantly. Limited health education, inadequate health healthcare infrastructure and cultural stigma around urological issues prevent many patients from seeking medical attention. This results in underdiagnosis and a lower adoption rate of both pharmacological and surgical treatment options
Benign Prostatic Hyperplasia Prostate Treatment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.8% |
|
Base Year Market Size (2024) |
USD 7.86 billion |
|
Forecast Year Market Size (2037) |
USD 16.09 billion |
|
Regional Scope |
|
Benign Prostatic Hyperplasia Prostate Treatment Segmentation
Treatment Type (Drug Treatment, Surgical Treatment)
The drug treatment segment in benign prostatic hyperplasia prostate treatment market is projected to witness noteworthy growth over the forecast period. The growth of the drug treatment segment is attributed to the rising consumption of drugs across the world. Furthermore, with companies receiving FDA approvals for the treatment of the disease also boosts the market growth significantly. In May 2024, Sumitomo Pharma America, Inc. received U.S. FDA approval for its vibegron (GEMTESA), a beta-3 adrenergic receptor (β3) agonist, supplemental New Drug Application (sNDA), for treating men with overactive bladder symptoms receiving pharmacological therapy for benign prostatic hyperplasia (BPH).
Therapeutic Class (BPH Devices, Transurethral RF Thermal Therapy, Suture Base Implant, Others, BPH Drugs, Alpha Blocker, Muscarinic Receptor Antagonist, 5-Alpha Reductase Inhibitors)
The BPH drugs segment is predicted to hold the largest share over the forecast period owing to its non-invasive nature, ease of administration, and widespread availability. The rising preference for hormonal therapies and anticholinergic drugs in patients with mild to moderate symptoms further boosts market growth. Combination therapies are gaining popularity for better clinical outcomes, while ongoing advancements in oral drug formulations and targeted therapies further strengthen the segment’s dominance.
Our in-depth analysis of the global benign prostatic hyperplasia prostate treatment market includes the following segments:
|
By Treatment Type |
|
|
By Therapeutic Class |
|
|
By Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportBenign Prostatic Hyperplasia Prostate Treatment Industry - Regional Synopsis
North America Market Forecast
The North America market is projected to hold the largest market share by the end of 2037. The growth of the market can be ascribed to the increasing unhealthy lifestyle, and a higher prevalence of benign prostatic hyperplasia. Furthermore, the presence of major key players, rapidly growing healthcare infrastructure of the region, coupled with the surge in novel drug delivery systems are further projected to influence the growth of the market positively over the forecast period.
The U.S. benign prostatic hyperplasia prostate treatment market is well-established, driven by technological advancements, rising health insurance coverage, and growing preference for minimally invasive procedures. Moreover, as per the data released by the United States Census Bureau, May 2023, about 1 in 6 people in the United States were aged 65 and over in 2020. The older population touched 55.8 million, meaning 16.8% of the total population in the country in the same year. The rapidly widening aging population, coupled with increasing awareness campaigns, is leading to early diagnosis and higher treatment adoption in the U.S.
Asia Pacific Market Forecast
The APAC benign prostatic hyperplasia prostate treatment market is growing due to the region’s aging population, rising healthcare access, and increasing awareness of prostate health. The market is driven by demand for both pharmacological treatments such as alpha-blockers and 5-alpha reductase inhibitors, as well as minimally invasive procedures such as laser therapy. Technological advancements, combined with patient preference for non-invasive solutions, are shaping the market’s evolution across countries such as China, Japan, and India.
India market is expanding due to a growing elderly population, and improved access to urology care. For instance, in May 2024, RG Hospitals announced a groundbreaking advancement in prostate treatment by launching RG NexGen Prostate Treatment- Nano Slim MiPS (Minimally Invasive Prostate Surgery). Government health initiatives, rising medical tourism, and advancements in treatment technologies are further boosting the country’s market growth.
Companies Dominating the Benign Prostatic Hyperplasia Prostate Treatment Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Cardinal Health Inc.
- NxThera, Inc.
- Veru, Inc.
- Teleflex Incorporated
- Eli Lily & Company
- Sanofi S.A.
- GSK plc
- Mylan N.V.
- AbbVie Inc.
Key strategies adopted by the benign prostatic hyperplasia prostrate treatment market include product launches, strategic partnerships and acquisitions, and geographical expansions. Additionally, players are focusing on regulatory approvals, patient awareness campaigns, and affordable pricing strategies to enhance market penetration and gain a competitive edge. Some of these companies are:
In the News
- In June 2024, Boston Scientific Corporation announced the acquisition of Silk Road Medical, Inc. at a purchase price of USD 27.50 per share, totalling to an enterprise value of nearly USD 1.16 billion.
- In April 2024, Teleflex Incorporated announced the launch of the Advanced Tissue Control (ATC) feature on its unified UroLift 2 System platform designed for the treatment of benign prostatic hyperplasia (BPH) symptoms in men with all prostate types up to 100g.
- In December 2021, Veru Inc. received approval from the U.S. FDA for its finasteride and tadalafil capsules, known as ENTADFI, which is used to treat urinary tract symptoms caused as a result of an enlarged prostate, commonly known as BPH.
Author Credits: Radhika Pawar
- Report ID: 4218
- Published Date: Mar 04, 2025
- Report Format: PDF, PPT
